The world needs a vaccine against COVID-19, and with some 200 vaccine candidates in various stages of development, and more than 30 of these vaccines already in Phase 3 clinical trials, odds are we will get a vaccine — probably several — sooner than you might expect. J.P. Morgan analyst Cory Kasimov focused in on two of the leading candidates: mRNA-1273 from Moderna (MRNA), and BNT162 from BioNTech (BNTX), laying odds on which of the two has the best chance of success — and which might win FDA approval first.Kasimov’s note, it should be pointed out, is not intended to …read more
Source:: Yahoo Finance